## Forfatterskabserklæring • Ugeskrift for Læger

Det er derfor vigtigt, at alle forfatteroplysninger skrives direkte ind i formularen, de disse er obligatoriske, hvorefter den kan printes og underskrives. For artikler til Danish Medical Journal skal Authorship Declaration for DMJ udfyldes.

Betydning ast	lanciennited og ologovariation for forfladigelse af
Manuskriptets titel:	de la
- CA CALLOWY	3 / 3
UFL-nr. – (hvis kendt):	Artikeltype.: Jokewtikel

### Hermed erklæres og indestås for,

- at det i manuskriptet præsenterede arbejde ikke, hverken helt eller delvist, er publiceret andetsteds, og at det ikke for tiden vurderes i anden tidsskriftsredaktion,
- at der ikke foreligger ophavsretlige problemer i forbindelse med publikation af manuskriptet og at der er indhentet nødvendige copyrighttilladelser og patientsamtykker til illustrationer, figurer og fotos inkl. evt. personer på billedet,
- at nødvendige tilladelser og patientsamtykker til benyttelse af patientoplysninger, laboratoriedata, billedediagnostiske og patologiske undersøgelser osv. foreligger,
- at manuskriptet, såfremt det udgår fra en institution eller afdeling, er accepteret til fremsendelse i den foreliggende form af den ansvarlige på institutionen eller afdelingen.
- at, såfremt flere institutioner eller afdelinger har været involveret i et omtalt patientforløb, er alle relevante parter orienteret inden indsendelse af manuskriptet,
- at personer og institutioner, der er nævnt i taksigelsesafsnittet, har accepteret dette,

Korrespondanceansvarlig forfatter:

- at det i manuskriptet præsenterede arbejde, indtil det publiceres på www.ugeskriftet.dk eller i Ugeskrift for Læger, eller afvises, ikke vil blive publiceret andetsteds, herunder i nyhedsmedier, uden forudgående aftale med redaktionen,
- at alle forfattere opfylder alle fire kriterier for forfatterskab, jf. Vancouverreglerne: 1) Væsentlige bidrag til idé eller design af arbejdet, eller tilvejebringelse, analyse eller fortolkning af arbejdet. 2) Manuskriptudarbejdelse eller kritisk indholdsmæssig manuskriptrevision. 3) Godkendelse af det endelige manuskript. 4) Tilsagn om at være ansvarlig for alle aspekter i manuskriptet, idet man sikrer sig, at spørgsmål om nøjagtighed eller lødighed i enhver del af arbejdet er tilstrækkeligt undersøgt og løst.
- at bilaget "ICMJE DISCLOSURE FORM" er udfyldt og indsendt sammen med "Forfatterskabserklæring",
- at såfremt Ugeskrift for Læger publicerer det indsendte materiale, overfører vi hermed al publiceringsrettighed til Ugeskrift for Læger. Dette gælder ved publikation i enhver form og i ethvert medie,
- at artiklen publiceres under Open Access Creative Commons licens CC BY-NC-ND 4.0.

Navn: WENNIG GROMBEN

Adresse: LEVER-, MAVE- y TARM SHENWE AAHU VNI VENETET MUDTING

Telefon i dagtimerne:

E-mail: hengroe Orm. dk

Et forfatterskab forudsætter, at man opfylder alle fire kriterier for forfatterskab if Vancouverreglerne, nævnt ovenfor

Et forfatterskab forudsætter, at man opfylder alle fire kriterier for forfatterskab jf. Vancouverreglerne, nævnt ovenfor. Dette gælder også alle dem, der i multicenterstudier fremstår som forfattere. Alle andre, der har bidraget til arbejdet, og som ikke er medforfattere, skal nævnes under Taksigelser og det skal beskrives, hvad de har bidraget med. Taksigelser kan tilføjes på side 2 af dette dokument.

Manuskriptets forfattere (alle felter for hver forfatter skal udfyldes)

Navn	Institution / afdeling	Underskrift
Henny Green ba	1 2MT, AUH	AH .
Kasmus H. Gartzer	1 LMT, AUH	Davinte III
	•	

# Taksigelser: Manuskriptets titel: Alle der har bidraget til arbejdet på manuskriptet, men som ikke opfylder alle fire kritierier for forfatterskab jf. Vancouverreglerne, skal nævnes under Taksigelser og det skal beskrives, hvad de har bidraget med. Det er forfatternes ansvar, at alle personer og institutioner, der nævnes under Taksigelser, har accepteret dette. Taksigelser (alle felter for hver person/institution skal udfyldes) Person / Institution Bidrag Lager på Afd. Latt, Auth.

# **ICMJE DISCLOSURE FORM**

Please save/export the filled in **form as PDF** before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Dat	<b>e</b> : 30. september 2024		
You	r name: Henning Grønba	ek	
Mai	nuscript title: Betydn	ing af anciennitet og døgnva	ariation for forfladigelse af det akademiske lægesprog
Mai	nuscript number (if known	):	
are rethird comress to a second comment of the a secon	elated to the content of yo parties whose interests manitment to transparency are relationship/activity/interest ollowing questions apply to ascript only.  Buthor's relationships/activity of the epidemiology of ypertensive medication, experienced and the content of the epidemiology of	ur manuscript. "Related" ay be affected by the content does not necessarily in est, it is preferable that you the author's relationship ities/interests should be go hypertension, you should yen if that medication is not port for the work reporter	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plan	ning of the work	
1	All support for the present	<b>⊠</b> None	
	manuscript (e.g., funding,		
	provision of study		
	materials, medical writing, article processing charges,		
	etc.)		
	No time limit for this		
	item.		
			Click TAB in last row to add extra rows
Tim	e frame: past 36 months		
	e frame, past 30 months		
2	Grants or contracts from	□ None	
	any entity (if not indicated	Abbvie, Intercept, ARLA	Research grants
	in item #1 above).	Food for Health, ADS AIPHIA Development Services AG	
2	Povalties or licenses	M Nama	

4	Consulting fees	□ None	
	Ü	NOVO, Pfizer,	
		AstraZeneca.	
5	Payment or honoraria for	□ None	
	lectures, presentations,	AstraZeneca, EISAI	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	<b>⊠</b> None	
	testimony		
7	Support for attending	<b>⊠</b> None	
	meetings and/or travel		
8	Patents planned, issued or	⊠ None	
	pending		
9	Participation on a Data	☐ None	
	Safety Monitoring Board or Advisory Board	CAMURUS AB	
10	Leadership or fiduciary	⊠ None	
	role in other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	<b>☑</b> None	
	Receipt of equipment,	<b>⊠</b> None	
	materials, drugs, medical writing, gifts or other services		
13	Other financial or non- financial interests	<b>⊠</b> None	

Please place an "X" next to the following statement to indicate your agreement:

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

ease save/export <b>the filled in form as PDF before submitting</b> it to Ugeskrift for Læg edical Journal.	er or Danish

# **ICMJE DISCLOSURE FORM**

Please save/export the filled in **form as PDF** before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Dat	<b>e</b> : 30. september 2024		
You	<b>r name</b> : Rasmus Hvidbje	erg Gantzel	
Mai	<del>-</del>	_ <del></del>	ariation for forfladigelse af det akademiske lægesprog
	nuscript number (if known		
are ro third comr list a	elated to the content of yo parties whose interests ma nitment to transparency ar relationship/activity/intere	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit ent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so.
	uscript only.	·	
perta antih In ite	ins to the epidemiology of ypertensive medication, ev	hypertension, you should yen if that medication is n port for the work reported	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.  d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim	e frame: Since the initial plan		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	⊠ None	
			Click TAB in last row to add extra rows
Time	e frame: past 36 months		CHER TAD III last TOW to dud extra fows
Шп	e trame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	<b>⊠</b> None	
3	Royalties or licenses	<b>⊠</b> None	

4	Consulting fees	⊠ None	
5	Payment or honoraria for	⊠ None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
	eddedional events		
6	Payment for expert	⊠ None	
	testimony		
7	Support for attending	⊠ None	
	meetings and/or travel		
8	Patents planned, issued or	M Name	
٥	pending	⊠ None	
	penamg		
9	Participation on a Data	<b>⊠</b> None	
	Safety Monitoring Board or Advisory Board		
	or Advisory Board		
10	Leadership or fiduciary	⊠ None	
	role in other board,		
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	⊠ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<b>⊠</b> None	
13	Other financial or non- financial interests	⊠ None	

Please place an "X" next to the following statement to indicate your agreement:

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

### IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.